| | DMC | Study design | Source | Number of ΔmiRNAs | Selected differentially expressed miRNA | Ref |
| | DR | STZ-DM rats versus controls | Retinas | Δ86 | ↑ 31, 31, 34b-3p, 34c, 184,199a, 200a, 200b, 205, 223, 335-3p, 378, 488, 574-3p
↓ 20b, 499, 690
(17 PCR-validated miRNAs) | [22] | | REC | Δ120 | ↑ 15b, 19b, 21, 31, 132, 142-3p, 146a, 155, 339-5p, 342-3p, 450a
↓ 20b-5p, 29c, 181c, 136, 376c
(16 PCR-validated miRNAs) | | db/db mice versus controls | Retinas | Δ6 | ↑ 21, 31, 132, 184, 379, 322
↓ 29b, 294, 376b, 690, 712
(>2-fold increase) | [41] | | DM2 patients versus controls | REC | ↑ 60, ↓ 16 | ↑ 133 ↓ 10a, 10b, 15a
(4 PCR-validated miRNAs) | [21] |
| | DSPN | STZ-DM mice versus controls | DRG | ↑ 74
↓ 68 | ↓ let-7i, 103, 16, 107, 130a, 30a, 29a, 138, 27a, 27b, let7g, 30b, let7f, 34a, 338-3p
↑ 191, 466-5p, 149, 341
(>1.5 fold-change) | [51] | | STZ-DM mice versus controls | Spinal dorsal horn | ↑ 21
↓ 21 | ↑ 184-5p ↓190a-5p
(2 PCR-validated miRNAs) | [137] |
| | DN | DN
FSGS
IgAN
MPGN
Controls | Human glomeruli | DN: Δ18
FSGS: Δ12
IgAN: Δ2
MPGN: Δ17
versus controls | DN versus controls:
↑ 29a, 23a, 214, 21, 5585, 589, 150, 4286
↓ 486-3p, 486-5p, 1180, 4301, 30a-3p, 30c, 148a, 30a-5p, 3184, 423
DN versus FSGS: ↑ 24, 146a
DN versus MPGN:↑ 146a, 146b; ↓ 671 | [37] | | DM2 patients versus healthy controls | Kidney | ↑ 32
↓ 39 | ↑ 146a, 155
(2 PCR-validated miRNAs) | [28] | | db/db mice versus controls | Glomeruli | ↓ 45 | ↓ 5 | ↓ 92a, 92b, 93, 140, 191 | [55] | | HG versus NG | Podocytes | ↓ 32 | | GEC | ↓ 86 |
|
|
